Cargando…

Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?

Evidence-based guidelines have undergone an incredible transformation over the last number of years. Significant advances include explicit linkages of systematic evidence summaries to the strength and direction of recommendations, consideration of all patient-important factors, transparent reporting...

Descripción completa

Detalles Bibliográficos
Autores principales: Rochwerg, Bram, Schünemann, Holger J., Raghu, Ganesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748604/
https://www.ncbi.nlm.nih.gov/pubmed/26860831
http://dx.doi.org/10.1186/s12916-016-0563-0
_version_ 1782415150678016000
author Rochwerg, Bram
Schünemann, Holger J.
Raghu, Ganesh
author_facet Rochwerg, Bram
Schünemann, Holger J.
Raghu, Ganesh
author_sort Rochwerg, Bram
collection PubMed
description Evidence-based guidelines have undergone an incredible transformation over the last number of years. Significant advances include explicit linkages of systematic evidence summaries to the strength and direction of recommendations, consideration of all patient-important factors, transparent reporting of the recommendation generation process including conflict of interest management strategies and the production of clinical practice guidelines which use simple and clear language. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology provides a framework for guideline development and was employed to produce the recently published ATS/ERS/JRS/ALAT update on treatment for idiopathic pulmonary fibrosis (IPF). Herein we discuss the advantages of using an evidence-based approach for guideline development using the IPF process and resultant document as an example.
format Online
Article
Text
id pubmed-4748604
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47486042016-02-11 Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? Rochwerg, Bram Schünemann, Holger J. Raghu, Ganesh BMC Med Commentary Evidence-based guidelines have undergone an incredible transformation over the last number of years. Significant advances include explicit linkages of systematic evidence summaries to the strength and direction of recommendations, consideration of all patient-important factors, transparent reporting of the recommendation generation process including conflict of interest management strategies and the production of clinical practice guidelines which use simple and clear language. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology provides a framework for guideline development and was employed to produce the recently published ATS/ERS/JRS/ALAT update on treatment for idiopathic pulmonary fibrosis (IPF). Herein we discuss the advantages of using an evidence-based approach for guideline development using the IPF process and resultant document as an example. BioMed Central 2016-02-10 /pmc/articles/PMC4748604/ /pubmed/26860831 http://dx.doi.org/10.1186/s12916-016-0563-0 Text en © Rochwerg et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Rochwerg, Bram
Schünemann, Holger J.
Raghu, Ganesh
Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?
title Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?
title_full Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?
title_fullStr Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?
title_full_unstemmed Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?
title_short Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?
title_sort idiopathic pulmonary fibrosis – clinical management guided by the evidence-based grade approach: what arguments can be made against transparency in guideline development?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748604/
https://www.ncbi.nlm.nih.gov/pubmed/26860831
http://dx.doi.org/10.1186/s12916-016-0563-0
work_keys_str_mv AT rochwergbram idiopathicpulmonaryfibrosisclinicalmanagementguidedbytheevidencebasedgradeapproachwhatargumentscanbemadeagainsttransparencyinguidelinedevelopment
AT schunemannholgerj idiopathicpulmonaryfibrosisclinicalmanagementguidedbytheevidencebasedgradeapproachwhatargumentscanbemadeagainsttransparencyinguidelinedevelopment
AT raghuganesh idiopathicpulmonaryfibrosisclinicalmanagementguidedbytheevidencebasedgradeapproachwhatargumentscanbemadeagainsttransparencyinguidelinedevelopment